KOSDAQBiotech & Pharma0088M0

Mezoo

₩13,960▲ 1.01%2026-11-18 close
Market Cap
₩137.9B
Turnover
₩1.4B
Volume
100K
Shares out.
9.9M
PER
—
PBR
—
EPS
—
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

From narrowing losses to quarterly profit, a model under test

Mezoo cut its operating loss to KRW 2.83 billion in 2025 and posted positive operating profit in every quarter from Q1 through Q3 2026. The next checks are the 2026 annual report and whether reimbursement fees begin to apply.

  1. 1

    Q3 2026 revenue was KRW 6.1 billion, up 7.6% from the prior quarter, and operating profit was KRW 2.09 billion, up 139.3%.

  2. 2

    2025 revenue was KRW 7.38 billion, up 211.8% from the prior year, and the operating loss narrowed to KRW 2.83 billion. Net profit attributable to controlling shareholders turned to KRW 2.76 billion in profit.

  3. 3

    The 2025 operating margin was -38.4%, improved from -251.5% in 2024 but still in loss territory. Operating cash flow remained negative at -KRW 5.39 billion in 2025.

  4. 4

    Q2 2026 operating profit was KRW 875 million, down 8.6% from Q1, so quarterly progress has not been a straight line.

  5. 5

    Cumulative operating profit for January to September 2026 was KRW 3.924 billion, a different path from the operating loss the listing prospectus had anticipated for 2026. Q3 operating margin was reported at about 34.3% (preliminary, disclosed October 29, 2026).

02

Business structure

Mezoo is a wearable patient-monitoring company founded in 2018, built around the HiCardi line of patch-type biosignal devices and the LiveStudio monitoring software platform.

Sales of the HiCardi M350 wireless patch, launched in Q2 2026, drove the Q3 2026 growth, and the company said new hospital adoption and repeat purchases by existing customers both rose.

Revenue comes from device sales, software subscriptions, and a share of health insurance fees that hospitals bill when they deliver the service.

Distribution combines direct sales with partner channels, and the expansion of domestic hospital supply has been attributed in part to a stronger sales push by distribution partner Dong-A ST. The CEO said that as of June 2026 the company had 29 tertiary general hospitals and 106 general hospitals as adopters.

Overseas, the company says it has entered more than 19 countries on the basis of FDA and CE approvals.

The product line targets both ECG recording and inpatient monitoring; the SpO2 measurement function received a Ministry of Food and Drug Safety change approval in September 2026, and approval for blood pressure measurement is being pursued.

Competitors include other Korean ECG patch makers, and a wearable monitoring peer, Seers, reported a sharp Q3 2026 revenue drop after supply disruptions for servers and core components.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3———
2025Q4———
2026Q1₩3.9B₩1B24.5%
2026Q2₩5.7B₩900M15.4%
2026Q3₩6.1B₩2.1B34.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2024₩2.4B-₩6B-₩7.1B−251.5%—−153.3%
2025₩7.4B-₩2.8B₩2.8B−38.4%27.6%39.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue rose from KRW 2.37 billion in 2024 to KRW 7.38 billion in 2025, up 211.8% year on year. Over the same period the operating loss narrowed from KRW 5.95 billion to KRW 2.83 billion, and the operating margin improved from -251.5% to -38.4%.

Mezoo posted operating losses in both 2024 and 2025, two consecutive years of loss, with the size of the loss reduced.

Net profit attributable to controlling shareholders swung from a net loss of KRW 7.07 billion in 2024 to a profit of KRW 2.76 billion in 2025, and net profit including non-controlling interests moved from a net loss of KRW 7.07 billion to KRW 2.76 billion.

Because an operating loss and a net profit appeared in the same year, the items that bridged the two levels need to be checked in the detailed filings to be identified accurately.

Equity attributable to the total equity at year-end 2025 was KRW 9.99 billion, of which KRW 9.99 billion belonged to controlling shareholders, against total liabilities of KRW 3.97 billion, and the debt ratio moved from -153.3% in 2024 to 39.7% in 2025.

Operating cash flow was -KRW 4.92 billion in 2024 and -KRW 5.39 billion in 2025, negative in both years.

Quarterly revenue bottomed at KRW 3.91 billion in Q1 2026, rose to KRW 5.67 billion in Q2 (up 45.0% from the prior quarter), and reached KRW 6.1 billion in Q3 (up 7.6%), so revenue has grown for two consecutive quarters from Q2 through Q3 2026.

Operating profit was KRW 957 million in Q1, KRW 875 million in Q2 (down 8.6% from the prior quarter), and KRW 2.09 billion in Q3 (up 139.3%), and in Q3 the profit increase far outpaced the revenue increase, indicating margin improvement.

Net profit attributable to controlling shareholders was KRW 955 million in Q1, KRW 1.1 billion in Q2 (up 14.9%), and KRW 2.3 billion in Q3 (up 109.7%), and the sum for the last four quarters (Q1 2025 to Q4 2025) was KRW 2.76 billion.

Cumulative revenue for January to September 2026 was KRW 15.675 billion and cumulative operating profit was KRW 3.924 billion, based on the preliminary disclosure of October 29, 2026.

05

Industry analysis

The domestic wearable patient-monitoring market is described as still in an early diffusion stage. In a July 2026 interview with Seoul Economic Daily, the CEO said domestic companies held about 30,000 hospital beds as of 2025, only 5% of the total. That figure points to a race for bed capacity that has only just begun.

The company has set a 2026 target of securing 10,000 to 12,000 beds. Among peers, a wearable monitoring company, Seers, reported that Q3 2026 revenue fell sharply and turned to an operating loss after server supply disruptions.

Reports attributed the shortage to imbalances in servers and core components caused by heavier AI infrastructure investment. Mezoo, by contrast, kept growing on higher sales of new products, so the two companies' results diverged. Other Korean makers of ECG patch devices also compete in this segment.

The company profile cites regulatory approvals, clinical validation, and insurance fee recognition as entry barriers. In terms of cycle position, Mezoo is in a diffusion phase in which it is adding hospital adopters after new product launches, and overseas expansion is tied to the planned U.S. entry in 2027.

06

Outlook

The CEO set 2026 targets of KRW 20 billion in revenue and KRW 7 billion to 8 billion in operating profit (per a July 2026 interview). Cumulative revenue for January to September 2026 of KRW 15.675 billion already exceeded the pre-listing full-year estimate, reported variously as KRW 15 billion or KRW 15.4 billion.

Among brokers, Hana Securities said in a May 2026 report that, including the LiveStudio central monitoring system, Mezoo was likely to exceed the KRW 15.4 billion revenue guidance it had presented at that time.

The SpO2 function received a Ministry of Food and Drug Safety change approval in September 2026, and approval for blood pressure measurement is being pursued. The company said it will continue advancing measurement-function upgrades and groundwork for reimbursement-fee coverage.

No public schedule has been announced for when reimbursement fees will apply, and once they do, the pace of revenue recognition could change through the billing structure with hospitals. Overseas, the company has described a U.S. market entry planned for 2027, per the July 2026 interview.

Management said M350 device sales and platform revenue both grew, and whether those two drivers keep growing will set the benchmark for the outlook. The next checkpoint is the 2026 annual report, which will allow annual revenue and operating profit to be compared directly with company targets.

07

Valuation

PER
—
PBR
—
ROE
27.6%
EPS
—
BPS
—
Dividend per share
₩0

Valuation multiples need to be read separately from the period before Mezoo turned profitable in 2025 and posted quarterly operating profit in 2026.

The sum of net profit attributable to controlling shareholders over the last four quarters, KRW 2.76 billion, is still small, so earnings-based multiples are sensitive to quarter-to-quarter swings.

On the Valueline screen as of late October 2026, the five-year average PER and PBR were higher than the multiples shown at that time. On a price-to-book basis, the share price remains above book value. The dividend yield is effectively negligible, so dividends are of little help in gauging the share price level.

As of June 2026, the largest shareholder group held 39.81%, and the free float ratio was 56.13%.

If the company's 2026 targets of KRW 20 billion in revenue and KRW 7 billion to 8 billion in operating profit are confirmed, the earnings base would widen, and the multiple comparison will be clearer once full-year figures are settled.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Revenue up for two consecutive quarters

Quarterly revenue rose from KRW 3.91 billion in Q1 2026 to KRW 5.67 billion in Q2 (up 45.0%) and KRW 6.1 billion in Q3 (up 7.6%). The company attributed the gains to higher M350 sales and growth in LiveStudio revenue.

Cumulative January to September 2026 revenue of KRW 15.675 billion is based on the preliminary disclosure of October 29, 2026.

Signs of quarterly margin improvement

Q3 operating profit of KRW 2.09 billion rose 139.3% from the prior quarter, with an operating margin reported at about 34.3% (preliminary, disclosed October 29, 2026). Compared with the -38.4% operating margin for 2025, quarters since have moved out of loss territory. Profit growth outpacing revenue growth is read as margin improvement from a larger sales base.

Room to expand through approvals and reimbursement

The company has entered more than 19 countries on FDA and CE approvals and has described a U.S. entry planned for 2027. The SpO2 function received a change approval in September 2026, and blood pressure approval is being pursued. Progress on reimbursement-fee groundwork could support wider inpatient ward monitoring.

09

Bear factors

Two years of losses and cash outflows

Mezoo recorded operating losses in both 2024 and 2025, and the 2025 operating margin was -38.4%. The continued losses meant more cash went out than came in from operating activities. Whether the 2026 quarterly profits convert into cash will need to be seen in full-year figures.

Short quarterly history and near-term swings

Only three quarters, from Q1 to Q3 2026, are available as disclosed quarterly results. Q2 operating profit fell 8.6% from Q1, and net profit attributable to controlling shareholders moved at a different pace from operating profit. The history is too short to establish a firm trend.

Reliance on distribution partners and components

Domestic supply expansion depends in part on the sales capacity of a distribution partner. In the same market, Seers reportedly saw Q3 2026 revenue fall sharply after supply disruptions for servers and core components.

Mezoo's component sourcing is not described in detail in public materials, so the scale of its supply risk is hard to gauge.

10

Risk factors

Regulation and reimbursement

Groundwork for reimbursement-fee coverage is underway, but no public schedule has been set for when fees will apply. Coverage is tied to hospital billing and could affect how quickly revenue is recognized.

The blood pressure function still needs Ministry of Food and Drug Safety approval, and any delay would slow feature expansion.

Supply chain and partners

Seers' Q3 2026 server shortage was reported to stem from imbalances in key components caused by heavier AI infrastructure spending. Mezoo's domestic supply depends partly on its partner's sales channels, so a shift in partner activity or component sourcing could quickly move quarterly revenue.

Cash flow and balance sheet

Operating cash flow stayed negative at -KRW 4.92 billion in 2024 and -KRW 5.39 billion in 2025. At year-end 2025, total equity was KRW 9.99 billion and total liabilities were KRW 3.97 billion, a debt ratio of 39.7%. Whether 2026 quarterly profits translate into cash should be checked against the 2026 annual report.

11

What to watch next

  1. Late March 2027

    The filing deadline for the 2026 annual report, when full-year revenue, operating profit, and operating cash flow are formally confirmed. It is the first confirmed figure against the company's targets of KRW 20 billion in revenue and KRW 7 billion to 8 billion in operating profit.

  2. Early 2027 (date not set)

    The point at which Q4 2026 results first become visible. The key check is whether the Q3 operating margin of about 34.3% holds in Q4.

  3. After November 2026 (timing undetermined)

    Whether the Ministry of Food and Drug Safety approves the blood pressure function. Approval would widen the feature set of the M350 and the scope of its ward monitoring offering.

  4. 2027 (company plan, month not specified)

    Whether the planned U.S. market entry moves into actual supply. The July 2026 interview set out this overseas revenue plan, and its execution will be visible in later disclosures.

12

Overall view

Mezoo still reported an operating loss of KRW 2.83 billion and revenue of KRW 7.38 billion for 2025, but quarterly operating profit moved into the black in 2026. Q3 revenue of KRW 6.1 billion and operating profit of KRW 2.09 billion rose 7.6% and 139.3% from the prior quarter, respectively.

Strengths include higher HiCardi M350 sales, growth in platform revenue, and overseas expansion built on approvals in more than 19 countries. Weaknesses include persistent negative operating cash flow, a short three-quarter record of disclosed quarterly results, and dependence on partner sales and component supply.

Reimbursement-fee coverage and the blood pressure approval could widen the revenue base, but neither has a public schedule. The 2026 annual report will allow full-year revenue and operating profit to be compared with company targets.

Because the earnings base is still small, multiple-based interpretation remains sensitive to quarterly swings. Overall, revenue growth and the shift to quarterly profit are shown in the figures, while cash flow and reimbursement coverage remain items to verify in future disclosures.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. thevc.kr
  2. comp.wisereport.co.kr
  3. m.news.nate.com
  4. m.sedaily.com
  5. valueline.co.kr
  6. sedaily.com
  7. edaily.co.kr
  8. sedaily.com
  9. sedaily.com
  10. sedaily.com
  11. vegannews.co.kr
  12. market-ink.co.kr
  13. knpnews.com
  14. sentv.co.kr
  15. msn.com
  16. paxetv.com
  17. news.bizwatch.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis